...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Clinical and diagnostic laboratory immunology >Specific serodiagnosis of human leishmaniasis with recombinant Leishmania P2 acidic ribosomal proteins.
【24h】

Specific serodiagnosis of human leishmaniasis with recombinant Leishmania P2 acidic ribosomal proteins.

机译：用重组利什曼原虫P2酸性核糖体蛋白对人利什曼病进行特异性血清学诊断。

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

The Leishmania P2 proteins have been analyzed as potential tools for the immunodiagnosis of human mucocutaneous and visceral leishmaniasis. Two recombinant Leishmania infantum proteins, rLIP2a and rLip2b, were used. The analysis indicated that the rLiP2a and rLiP2b proteins are recognized by 76% (16 of 21) and 42% (9 of 21), respectively, of sera from patients with mucocutaneous leishmaniasis and by 50% (5 of 10) and 40% (4 of 10), respectively, of sera from patients with visceral leishmaniasis. The Leishmania P2 proteins were engineered to have deletions of particular amino acids from the carboxyl-terminal region in order to avoid cross-reactivity with sera from patients with systemic lupus erythematosus and Chagas' disease, since it is known that this region is the main target of the autoantibodies present in sera from these patients. The results show that while the modified recombinant proteins rLiP2a-Q and rLiP2b-Q, in which the five carboxyl-terminal amino acids had been deleted, maintain the leishmaniasis-specific epitopes, they do not react with sera from patients with autoimmune disease and Chagas' disease. For this reason, and also because the sera from patients with tuberculosis and leprosy, diseases that have to be considered in a differential clinical diagnosis of infectious diseases, do not react with the rLiP2a-Q or rLiP2b-Q protein, we think that the engineered proteins may be considered specific tools for the immunodiagnosis of mucocutaneous and visceral leishmaniasis.
机译：利什曼原虫P2蛋白已被分析为人类粘膜皮肤和内脏利什曼病的免疫诊断的潜在工具。使用了两种重组婴儿利什曼原虫蛋白，rLIP2a和rLip2b。分析表明，rLiP2a和rLiP2b蛋白分别被粘膜皮肤利什曼病患者血清的76％（21中的16）和42％（21中的9）识别，分别被50％（10中的5）和40％（20％）识别。内脏利什曼病患者的血清分别有10个中的4个。为了避免系统性红斑狼疮和恰加斯氏病患者的血清与血清交叉反应，对利什曼原虫P2蛋白进行了改造，使其羧基末端区域中的特定氨基酸缺失，因为已知该区域是主要的靶标这些患者血清中存在的自身抗体中的多少。结果表明，尽管修饰的重组蛋白rLiP2a-Q和rLiP2b-Q（其中五个羧基末端氨基酸已被删除）保持了利什曼病的特异性表位，但它们不与自身免疫性疾病和恰加斯病患者的血清反应' 疾病。因此，并且由于结核病和麻风病患者的血清（在传染病的鉴别临床诊断中必须考虑的疾病）不会与rLiP2a-Q或rLiP2b-Q蛋白反应，我们认为蛋白可以被认为是粘膜皮肤和内脏利什曼病免疫诊断的特定工具。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号